Biomanufacturing Excellence Act of 2025
Summary
The Biomanufacturing Excellence Act of 2025 aims to establish a National Biopharmaceutical Center of Excellence. This center would advance biopharmaceutical manufacturing, support good manufacturing practices, and promote collaboration between public, private, and nonprofit institutions. The Act authorizes $120 million for fiscal year 2026 to fund the center's activities.
Expected Effects
The Act is likely to stimulate innovation in biopharmaceutical manufacturing and reduce dependency on foreign supply chains. It could also improve workforce training and development in the biotechnology sector. The establishment of the center may lead to better and less invasive medical treatments.
Potential Benefits
- Advances biopharmaceutical manufacturing technologies.
- Improves manufacturing processes and equipment.
- Reduces supply bottlenecks and strengthens supply chains.
- Supports workforce training and development.
- Facilitates collaboration among various institutions.
Potential Disadvantages
- The cost of \$120 million could strain the budget.
- The center's effectiveness depends on the quality of leadership and collaboration.
- Benefits may take several years to materialize.
- Potential for intellectual property disputes.
- Risk of the center duplicating existing efforts.
Constitutional Alignment
The Act appears to align with the Constitution's mandate to "promote the general Welfare" (Preamble). Congress's power to establish such a center falls under its enumerated powers in Article I, Section 8, which includes the power to regulate commerce and provide for the common defense. The Act does not appear to infringe on any specific constitutional rights or limitations.
Impact Assessment: Things You Care About ⓘ
This action has been evaluated across 19 key areas that matter to you. Scores range from 1 (highly disadvantageous) to 5 (highly beneficial).